title: VEGFA genomic amplification tailors treatment of HCCs with sorafenib.
abstract: In this issue of Cancer Discovery, Horwitz and colleagues identified a subtype of hepatocelluar carcinoma (HCC) bearing VEGFA genomic amplification that is particularly sensitive to VEGFA inhibition and is also more sensitive to sorafenib treatment. Taken conjointly, these data suggest that VEGFA genomic amplification can be used as a biomarker for personalized treatment of HCC with sorafenib.
authors.affiliation: Authors' Affiliation: Department of Pathology and Division of Biological Sciences, University of California San Diego, La Jolla, California.
authors.forename: Xiaolin
authors.initials: X
authors.lastname: Luo
authors.affiliation: Authors' Affiliation: Department of Pathology and Division of Biological Sciences, University of California San Diego, La Jolla, California gfeng@ucsd.edu.
authors.forename: Gen-Sheng
authors.initials: GS
authors.lastname: Feng
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D000077157:Sorafenib; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D042461:Vascular Endothelial Growth Factor A; D009536:Niacinamide; D000077157:Sorafenib